Petit Jean Michel, Benichou Muriel, Duvillard Laurence, Jooste Valerie, Bour Jean Baptiste, Minello Anne, Verges Bruno, Brun Jean Marcel, Gambert Philippe, Hillon Patrick
Services de Diabétologie et Endocrinologie, Dijon cedex, France.
Am J Gastroenterol. 2003 May;98(5):1150-4. doi: 10.1111/j.1572-0241.2003.07402.x.
A relationship between chronic hepatitis C virus (HCV) infection and lipid metabolism has recently been suggested. The aim of this study was to determine the correlation between lipid profile and virology, histologic lesions, and response to alpha interferon therapy in noncirrhotic, nondiabetic patients with hepatitis C.
A total of 109 consecutive untreated chronic hepatitis C patients were studied to assess the following: 1) the effects of HCV genotype, viral load, steatosis, hepatic fibrosis, and body mass index (BMI) on lipid profile; and 2) whether lipid parameters could predict response to antiviral therapy.
The control group showed a significantly higher apolipoprotein B (apoB) concentration compared with patients with chronic hepatitis C. Hypobetalipoproteinemia (apo B <0.7 g/L) was found in 27 (24.7%) chronic HCV patients and in five (5.3%) control subjects (p = 0.0002). Levels of apo B were negatively correlated with steatosis and HCV viral load (r = -0.22; p = 0.03). This last correlation was strong for non-1 genotype and genotype 3 (r = -0.48; p = 0.0005, and r = -0.47; p = 0.007, respectively) but was not found in genotype 1. In multivariate analysis, low apo B concentration was significantly associated with fibrosis grade 2 or 3 versus grade 0 or 1 (p < 0.001), steatosis >5% (p < 0.001), low body mass index (p < 0.001), and high HCV viral load (p < 0.014). No correlation was found in the 76 treated patients between apo B and response to interferon therapy.
In chronic HCV patients, hypobetalipoproteinemia occurs already in the early stages of HCV infection before the development of liver cirrhosis. The correlation between apo B levels and HCV viral load seems to confirm the interaction between hepatitis C infection and beta-lipoprotein metabolism.
最近有人提出慢性丙型肝炎病毒(HCV)感染与脂质代谢之间存在关联。本研究的目的是确定非肝硬化、非糖尿病丙型肝炎患者的血脂谱与病毒学、组织学病变以及对α干扰素治疗反应之间的相关性。
共对109例连续未治疗的慢性丙型肝炎患者进行研究,以评估以下内容:1)HCV基因型、病毒载量、脂肪变性、肝纤维化和体重指数(BMI)对血脂谱的影响;2)血脂参数是否可预测抗病毒治疗的反应。
与慢性丙型肝炎患者相比,对照组的载脂蛋白B(apoB)浓度显著更高。27例(24.7%)慢性HCV患者和5例(5.3%)对照者出现低脂蛋白血症(apo B<0.7 g/L)(p=0.0002)。apo B水平与脂肪变性和HCV病毒载量呈负相关(r=-0.22;p=0.03)。对于非1基因型和3基因型,这一相关性较强(分别为r=-0.48;p=0.0005和r=-0.47;p=0.007),但在1基因型中未发现。多变量分析显示,apo B浓度低与纤维化2级或3级相对于0级或1级显著相关(p<0.001)、脂肪变性>5%(p<0.001)、低体重指数(p<0.001)和高HCV病毒载量(p<0.014)。在76例接受治疗的患者中,未发现apo B与干扰素治疗反应之间存在相关性。
在慢性HCV患者中,低脂蛋白血症在肝硬化发生之前的HCV感染早期就已出现。apo B水平与HCV病毒载量之间的相关性似乎证实了丙型肝炎感染与β脂蛋白代谢之间的相互作用。